2010 was not a year of survival breakthroughs in hematologic malignancies. However, in Hodgkin's disease and multiple myeloma new therapies emerged as the standard of care and nilotinib may be considered the treatment choice for newly diagnosed chronic myeloid leukemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
07 June 2011
In the version of this article initially published online The permission details for Figure 1 in this article were missing. The correct permission statement should read: Reproduced with permission from Nature Publishing Group © Diehl, V. Nat. Rev. Clin. Oncol. 7, 301–302 (2010). The error has been corrected for the HTML and PDF versions of the article.
References
Engert, A. et al. Reduced treatment intensity in patients with early stage Hodgkin's lymphoma. N. Engl. J. Med. 363, 640–652 (2010).
Canellos, G. P., Abramson, J. S., Fisher, D. C. & LaCasce, A. S. Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J. Clin. Oncol. 28, 1611–1615 (2010).
Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362, 875–885 (2010).
Richardson, P. G. et al. Lenolidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679–686 (2010).
Laubauh, J. & Richardson, P. Bortezomib and dexamethasone induction for multiple myeloma. Nat. Rev. Clin. Oncol. 8, 8–10 (2011).
Anderson, K. C. et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study. J. Clin. Oncol. 28, (Suppl. 15), a8016 (2010).
Saglio, G. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362, 2251–2259 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
DeVita, V., Canellos, G. New therapies and standard of care in oncology. Nat Rev Clin Oncol 8, 67–68 (2011). https://doi.org/10.1038/nrclinonc.2010.221
Published:
Issue date:
DOI: https://doi.org/10.1038/nrclinonc.2010.221
